Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 122 entries
Sorted by: Best Match Show Resources per page
A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction.

Advances in medical education and practice

Kahn JS, Witteles RM, Mahaffey KW, Desai SA, Ozdalga E, Heidenreich PA.
PMID: 28814910
Adv Med Educ Pract. 2017 Aug 02;8:559-566. doi: 10.2147/AMEP.S138467. eCollection 2017.

INTRODUCTION: Satisfaction with training and with educational experiences represents important internal medicine (IM) programmatic goals. Graduates from IM residency programs are uniquely poised to provide insights into their educational and training experiences and to assess whether these experiences were...

Cite
Kahn JS, Witteles RM, Mahaffey KW, et al. A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction. Adv Med Educ Pract. 2017;8:559-566doi: 10.2147/AMEP.S138467.
Kahn, J. S., Witteles, R. M., Mahaffey, K. W., Desai, S. A., Ozdalga, E., & Heidenreich, P. A. (2017). A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction. Advances in medical education and practice, 8559-566. https://doi.org/10.2147/AMEP.S138467
Kahn, James S, et al. "A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction." Advances in medical education and practice vol. 8 (2017): 559-566. doi: https://doi.org/10.2147/AMEP.S138467
Kahn JS, Witteles RM, Mahaffey KW, Desai SA, Ozdalga E, Heidenreich PA. A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction. Adv Med Educ Pract. 2017 Aug 02;8:559-566. doi: 10.2147/AMEP.S138467. eCollection 2017. PMID: 28814910; PMCID: PMC5546589.
Copy Download .nbib Format: NLM
The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.

Clinical cardiology

Yong CM, Sundaram V, Abnousi F, Olivier CB, Yang J, Stone GW, Steg PG, Michael Gibson C, Hamm CW, Price MJ, Deliargyris EN, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW.
PMID: 31254472
Clin Cardiol. 2019 Jun 29; doi: 10.1002/clc.23221. Epub 2019 Jun 29.

BACKGROUND: The intravenous, rapidly acting P2Y12 inhibitor cangrelor reduces the rate of ischemic events during PCI with no significant increase in severe bleeding. However, the efficacy and safety of cangrelor compared with clopidogrel in patients treated with single vessel...

Cite
Yong CM, Sundaram V, Abnousi F, et al. The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clin Cardiol. 2019;doi: 10.1002/clc.23221.
Yong, C. M., Sundaram, V., Abnousi, F., Olivier, C. B., Yang, J., Stone, G. W., Steg, P. G., Michael Gibson, C., Hamm, C. W., Price, M. J., Deliargyris, E. N., Prats, J., White, H. D., Harrington, R. A., Bhatt, D. L., Mahaffey, K. W. (2019). The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clinical cardiology, . https://doi.org/10.1002/clc.23221
Yong, Celina M, et al. "The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX." Clinical cardiology vol. (2019). doi: https://doi.org/10.1002/clc.23221
Yong CM, Sundaram V, Abnousi F, Olivier CB, Yang J, Stone GW, Steg PG, Michael Gibson C, Hamm CW, Price MJ, Deliargyris EN, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW. The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clin Cardiol. 2019 Jun 29; doi: 10.1002/clc.23221. Epub 2019 Jun 29. PMID: 31254472; PMCID: PMC6727881.
Copy Download .nbib Format: NLM
Characterization and evaluation of lactic acid bacteria candidates for intestinal epithelial permeability and Salmonella Typhimurium colonization in neonatal turkey poults.

Poultry science

Yang Y, Latorre JD, Khatri B, Kwon YM, Kong BW, Teague KD, Graham LE, Wolfenden AD, Mahaffey BD, Baxter M, Hernandez-Velasco X, Merino-Guzman R, Hargis BM, Tellez G.
PMID: 29177460
Poult Sci. 2018 Feb 01;97(2):724. doi: 10.3382/ps/pex361.

No abstract available.

Cite
Yang Y, Latorre JD, Khatri B, et al. Characterization and evaluation of lactic acid bacteria candidates for intestinal epithelial permeability and Salmonella Typhimurium colonization in neonatal turkey poults. Poult Sci. 2018;97(2):724doi: 10.3382/ps/pex361.
Yang, Y., Latorre, J. D., Khatri, B., Kwon, Y. M., Kong, B. W., Teague, K. D., Graham, L. E., Wolfenden, A. D., Mahaffey, B. D., Baxter, M., Hernandez-Velasco, X., Merino-Guzman, R., Hargis, B. M., & Tellez, G. (2018). Characterization and evaluation of lactic acid bacteria candidates for intestinal epithelial permeability and Salmonella Typhimurium colonization in neonatal turkey poults. Poultry science, 97(2), 724. https://doi.org/10.3382/ps/pex361
Yang, Y, et al. "Characterization and evaluation of lactic acid bacteria candidates for intestinal epithelial permeability and Salmonella Typhimurium colonization in neonatal turkey poults." Poultry science vol. 97,2 (2018): 724. doi: https://doi.org/10.3382/ps/pex361
Yang Y, Latorre JD, Khatri B, Kwon YM, Kong BW, Teague KD, Graham LE, Wolfenden AD, Mahaffey BD, Baxter M, Hernandez-Velasco X, Merino-Guzman R, Hargis BM, Tellez G. Characterization and evaluation of lactic acid bacteria candidates for intestinal epithelial permeability and Salmonella Typhimurium colonization in neonatal turkey poults. Poult Sci. 2018 Feb 01;97(2):724. doi: 10.3382/ps/pex361. PMID: 29177460.
Copy Download .nbib Format: NLM
Canagliflozin review - safety and efficacy profile in patients with T2DM.

Diabetes, metabolic syndrome and obesity : targets and therapy

Jakher H, Chang TI, Tan M, Mahaffey KW.
PMID: 30787627
Diabetes Metab Syndr Obes. 2019 Feb 01;12:209-215. doi: 10.2147/DMSO.S184437. eCollection 2019.

Canagliflozin is a sodium glucose-cotransporter (SGLT) receptor inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). This article reviews the mechanism of action of SGLT-2 receptor inhibitors and the efficacy of canagliflozin as an antidiabetic agent, its...

Cite
Jakher H, Chang TI, Tan M, et al. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019;12:209-215doi: 10.2147/DMSO.S184437.
Jakher, H., Chang, T. I., Tan, M., & Mahaffey, K. W. (2019). Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes, metabolic syndrome and obesity : targets and therapy, 12209-215. https://doi.org/10.2147/DMSO.S184437
Jakher, Haroon, et al. "Canagliflozin review - safety and efficacy profile in patients with T2DM." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 12 (2019): 209-215. doi: https://doi.org/10.2147/DMSO.S184437
Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019 Feb 01;12:209-215. doi: 10.2147/DMSO.S184437. eCollection 2019. PMID: 30787627; PMCID: PMC6363491.
Copy Download .nbib Format: NLM
Risks Involved in the Use of Enrofloxacin for Salmonella Enteritidis or Salmonella Heidelberg in Commercial Poultry.

Frontiers in veterinary science

Morales-Barrera E, Calhoun N, Lobato-Tapia JL, Lucca V, Prado-Rebolledo O, Hernandez-Velasco X, Merino-Guzman R, Petrone-García VM, Latorre JD, Mahaffey BD, Teague KD, Graham LE, Wolfenden AD, Baxter MF, Hargis BM, Tellez G.
PMID: 27630995
Front Vet Sci. 2016 Aug 31;3:72. doi: 10.3389/fvets.2016.00072. eCollection 2016.

The objectives of the present study were to evaluate the risks involved in the use of Enrofloxacin for Salmonella Enteritidis (SE) or Salmonella Heidelberg (SH) in commercial poultry and determine the effects of a probiotic as an antibiotic alternative....

Cite
Morales-Barrera E, Calhoun N, Lobato-Tapia JL, et al. Risks Involved in the Use of Enrofloxacin for Salmonella Enteritidis or Salmonella Heidelberg in Commercial Poultry. Front Vet Sci. 2016;3:72doi: 10.3389/fvets.2016.00072.
Morales-Barrera, E., Calhoun, N., Lobato-Tapia, J. L., Lucca, V., Prado-Rebolledo, O., Hernandez-Velasco, X., Merino-Guzman, R., Petrone-García, V. M., Latorre, J. D., Mahaffey, B. D., Teague, K. D., Graham, L. E., Wolfenden, A. D., Baxter, M. F., Hargis, B. M., & Tellez, G. (2016). Risks Involved in the Use of Enrofloxacin for Salmonella Enteritidis or Salmonella Heidelberg in Commercial Poultry. Frontiers in veterinary science, 372. https://doi.org/10.3389/fvets.2016.00072
Morales-Barrera, Eduardo, et al. "Risks Involved in the Use of Enrofloxacin for Salmonella Enteritidis or Salmonella Heidelberg in Commercial Poultry." Frontiers in veterinary science vol. 3 (2016): 72. doi: https://doi.org/10.3389/fvets.2016.00072
Morales-Barrera E, Calhoun N, Lobato-Tapia JL, Lucca V, Prado-Rebolledo O, Hernandez-Velasco X, Merino-Guzman R, Petrone-García VM, Latorre JD, Mahaffey BD, Teague KD, Graham LE, Wolfenden AD, Baxter MF, Hargis BM, Tellez G. Risks Involved in the Use of Enrofloxacin for Salmonella Enteritidis or Salmonella Heidelberg in Commercial Poultry. Front Vet Sci. 2016 Aug 31;3:72. doi: 10.3389/fvets.2016.00072. eCollection 2016. PMID: 27630995; PMCID: PMC5005317.
Copy Download .nbib Format: NLM
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.

Cardiovascular research

Yu J, Li J, Leaver PJ, Arnott C, Huffman MD, Udell JA, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Rosenthal N, Neal B, Figtree GA.
PMID: 33826709
Cardiovasc Res. 2021 Apr 07; doi: 10.1093/cvr/cvab128. Epub 2021 Apr 07.

AIMS: Given the benefits of sodium glucose co-transporter 2 inhibition (SGLT2i) in protecting against heart failure in diabetic patients, we sought to explore the potential impact of SGLT2i on the clinical features of patients presenting with myocardial infarction (MI)...

Cite
Yu J, Li J, Leaver PJ, et al. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. Cardiovasc Res. 2021;doi: 10.1093/cvr/cvab128.
Yu, J., Li, J., Leaver, P. J., Arnott, C., Huffman, M. D., Udell, J. A., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Matthews, D. R., Shaw, W., Rosenthal, N., Neal, B., & Figtree, G. A. (2021). Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. Cardiovascular research, . https://doi.org/10.1093/cvr/cvab128
Yu, Jie, et al. "Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial." Cardiovascular research vol. (2021). doi: https://doi.org/10.1093/cvr/cvab128
Yu J, Li J, Leaver PJ, Arnott C, Huffman MD, Udell JA, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Rosenthal N, Neal B, Figtree GA. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. Cardiovasc Res. 2021 Apr 07; doi: 10.1093/cvr/cvab128. Epub 2021 Apr 07. PMID: 33826709.
Copy Download .nbib Format: NLM
Oceanographic and biogeochemical drivers cause divergent trends in the nitrogen isoscape in a changing Arctic Ocean.

Ambio

Buchanan PJ, Tagliabue A, de la Vega C, Mahaffey C.
PMID: 34628601
Ambio. 2022 Feb;51(2):383-397. doi: 10.1007/s13280-021-01635-6. Epub 2021 Oct 09.

Nitrogen stable isotopes (δ

Cite
Buchanan PJ, Tagliabue A, de la Vega C, et al. Oceanographic and biogeochemical drivers cause divergent trends in the nitrogen isoscape in a changing Arctic Ocean. Ambio. 2021;51(2):383-397doi: 10.1007/s13280-021-01635-6.
Buchanan, P. J., Tagliabue, A., de la Vega, C., & Mahaffey, C. (2022). Oceanographic and biogeochemical drivers cause divergent trends in the nitrogen isoscape in a changing Arctic Ocean. Ambio, 51(2), 383-397. https://doi.org/10.1007/s13280-021-01635-6
Buchanan, Pearse James, et al. "Oceanographic and biogeochemical drivers cause divergent trends in the nitrogen isoscape in a changing Arctic Ocean." Ambio vol. 51,2 (2022): 383-397. doi: https://doi.org/10.1007/s13280-021-01635-6
Buchanan PJ, Tagliabue A, de la Vega C, Mahaffey C. Oceanographic and biogeochemical drivers cause divergent trends in the nitrogen isoscape in a changing Arctic Ocean. Ambio. 2022 Feb;51(2):383-397. doi: 10.1007/s13280-021-01635-6. Epub 2021 Oct 09. PMID: 34628601.
Copy Download .nbib Format: NLM
A Novel Method of Isolating Myofibrils From Primary Cardiomyocyte Culture Suitable for Myofibril Mechanical Study.

Frontiers in cardiovascular medicine

Woulfe KC, Ferrara C, Pioner JM, Mahaffey JH, Coppini R, Scellini B, Ferrantini C, Piroddi N, Tesi C, Poggesi C, Jeong M.
PMID: 30838216
Front Cardiovasc Med. 2019 Feb 19;6:12. doi: 10.3389/fcvm.2019.00012. eCollection 2019.

Myofibril based mechanical studies allow evaluation of sarcomeric protein function. We describe a novel method of obtaining myofibrils from primary cardiomyocyte culture. Adult rat ventricular myocytes (ARVMs) were obtained by enzymatic digestion and maintained in serum free condition. ARVMs...

Cite
Woulfe KC, Ferrara C, Pioner JM, et al. A Novel Method of Isolating Myofibrils From Primary Cardiomyocyte Culture Suitable for Myofibril Mechanical Study. Front Cardiovasc Med. 2019;6:12doi: 10.3389/fcvm.2019.00012.
Woulfe, K. C., Ferrara, C., Pioner, J. M., Mahaffey, J. H., Coppini, R., Scellini, B., Ferrantini, C., Piroddi, N., Tesi, C., Poggesi, C., & Jeong, M. (2019). A Novel Method of Isolating Myofibrils From Primary Cardiomyocyte Culture Suitable for Myofibril Mechanical Study. Frontiers in cardiovascular medicine, 612. https://doi.org/10.3389/fcvm.2019.00012
Woulfe, Kathleen C, et al. "A Novel Method of Isolating Myofibrils From Primary Cardiomyocyte Culture Suitable for Myofibril Mechanical Study." Frontiers in cardiovascular medicine vol. 6 (2019): 12. doi: https://doi.org/10.3389/fcvm.2019.00012
Woulfe KC, Ferrara C, Pioner JM, Mahaffey JH, Coppini R, Scellini B, Ferrantini C, Piroddi N, Tesi C, Poggesi C, Jeong M. A Novel Method of Isolating Myofibrils From Primary Cardiomyocyte Culture Suitable for Myofibril Mechanical Study. Front Cardiovasc Med. 2019 Feb 19;6:12. doi: 10.3389/fcvm.2019.00012. eCollection 2019. PMID: 30838216; PMCID: PMC6389618.
Copy Download .nbib Format: NLM
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m.

Clinical journal of the American Society of Nephrology : CJASN

Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V.
PMID: 33214158
Clin J Am Soc Nephrol. 2020 Dec 07;15(12):1705-1714. doi: 10.2215/CJN.10140620. Epub 2020 Nov 19.

BACKGROUND AND OBJECTIVES: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participants with...

Cite
Bakris G, Oshima M, Mahaffey KW, et al. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m. Clin J Am Soc Nephrol. 2020;15(12):1705-1714doi: 10.2215/CJN.10140620.
Bakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., Levin, A., Neal, B., Oh, R., Pollock, C., Rosenthal, N., Wheeler, D. C., Zhang, H., Zinman, B., Jardine, M. J., & Perkovic, V. (2020). Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m. Clinical journal of the American Society of Nephrology : CJASN, 15(12), 1705-1714. https://doi.org/10.2215/CJN.10140620
Bakris, George, et al. "Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m." Clinical journal of the American Society of Nephrology : CJASN vol. 15,12 (2020): 1705-1714. doi: https://doi.org/10.2215/CJN.10140620
Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m. Clin J Am Soc Nephrol. 2020 Dec 07;15(12):1705-1714. doi: 10.2215/CJN.10140620. Epub 2020 Nov 19. PMID: 33214158; PMCID: PMC7769025.
Copy Download .nbib Format: NLM
The Project Baseline Health Study: a step towards a broader mission to map human health.

NPJ digital medicine

Arges K, Assimes T, Bajaj V, Balu S, Bashir MR, Beskow L, Blanco R, Califf R, Campbell P, Carin L, Christian V, Cousins S, Das M, Dockery M, Douglas PS, Dunham A, Eckstrand J, Fleischmann D, Ford E, Fraulo E, French J, Gambhir SS, Ginsburg GS, Green RC, Haddad F, Hernandez A, Hernandez J, Huang ES, Jaffe G, King D, Koweek LH, Langlotz C, Liao YJ, Mahaffey KW, Marcom K, Marks WJ, Maron D, McCabe R, McCall S, McCue R, Mega J, Miller D, Muhlbaier LH, Munshi R, Newby LK, Pak-Harvey E, Patrick-Lake B, Pencina M, Peterson ED, Rodriguez F, Shore S, Shah S, Shipes S, Sledge G, Spielman S, Spitler R, Schaack T, Swamy G, Willemink MJ, Wong CA.
PMID: 32550652
NPJ Digit Med. 2020 Jun 05;3:84. doi: 10.1038/s41746-020-0290-y. eCollection 2020.

The Project Baseline Health Study (PBHS) was launched to map human health through a comprehensive understanding of both the health of an individual and how it relates to the broader population. The study will contribute to the creation of...

Cite
Arges K, Assimes T, Bajaj V, et al. The Project Baseline Health Study: a step towards a broader mission to map human health. NPJ Digit Med. 2020;3:84doi: 10.1038/s41746-020-0290-y.
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., Blanco, R., Califf, R., Campbell, P., Carin, L., Christian, V., Cousins, S., Das, M., Dockery, M., Douglas, P. S., Dunham, A., Eckstrand, J., Fleischmann, D., Ford, E., Fraulo, E., French, J., Gambhir, S. S., Ginsburg, G. S., Green, R. C., Haddad, F., Hernandez, A., Hernandez, J., Huang, E. S., Jaffe, G., King, D., Koweek, L. H., Langlotz, C., Liao, Y. J., Mahaffey, K. W., Marcom, K., Marks, W. J., Maron, D., McCabe, R., McCall, S., McCue, R., Mega, J., Miller, D., Muhlbaier, L. H., Munshi, R., Newby, L. K., Pak-Harvey, E., Patrick-Lake, B., Pencina, M., Peterson, E. D., Rodriguez, F., Shore, S., Shah, S., Shipes, S., Sledge, G., Spielman, S., Spitler, R., Schaack, T., Swamy, G., Willemink, M. J., & Wong, C. A. (2020). The Project Baseline Health Study: a step towards a broader mission to map human health. NPJ digital medicine, 384. https://doi.org/10.1038/s41746-020-0290-y
Arges, Kristine, et al. "The Project Baseline Health Study: a step towards a broader mission to map human health." NPJ digital medicine vol. 3 (2020): 84. doi: https://doi.org/10.1038/s41746-020-0290-y
Arges K, Assimes T, Bajaj V, Balu S, Bashir MR, Beskow L, Blanco R, Califf R, Campbell P, Carin L, Christian V, Cousins S, Das M, Dockery M, Douglas PS, Dunham A, Eckstrand J, Fleischmann D, Ford E, Fraulo E, French J, Gambhir SS, Ginsburg GS, Green RC, Haddad F, Hernandez A, Hernandez J, Huang ES, Jaffe G, King D, Koweek LH, Langlotz C, Liao YJ, Mahaffey KW, Marcom K, Marks WJ, Maron D, McCabe R, McCall S, McCue R, Mega J, Miller D, Muhlbaier LH, Munshi R, Newby LK, Pak-Harvey E, Patrick-Lake B, Pencina M, Peterson ED, Rodriguez F, Shore S, Shah S, Shipes S, Sledge G, Spielman S, Spitler R, Schaack T, Swamy G, Willemink MJ, Wong CA. The Project Baseline Health Study: a step towards a broader mission to map human health. NPJ Digit Med. 2020 Jun 05;3:84. doi: 10.1038/s41746-020-0290-y. eCollection 2020. PMID: 32550652; PMCID: PMC7275087.
Copy Download .nbib Format: NLM
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.

European heart journal

Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Górriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL.
PMID: 34423370
Eur Heart J. 2021 Aug 23; doi: 10.1093/eurheartj/ehab497. Epub 2021 Aug 23.

AIMS: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin-aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2...

Cite
Neuen BL, Oshima M, Perkovic V, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;doi: 10.1093/eurheartj/ehab497.
Neuen, B. L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C., Bakris, G., Cannon, C. P., Charytan, D. M., Edwards, R., Górriz, J. L., Jardine, M. J., Levin, A., Neal, B., De Nicola, L., Pollock, C., Rosenthal, N., Wheeler, D. C., Mahaffey, K. W., & Heerspink, H. J. L. (2021). Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European heart journal, . https://doi.org/10.1093/eurheartj/ehab497
Neuen, Brendon L, et al. "Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial." European heart journal vol. (2021). doi: https://doi.org/10.1093/eurheartj/ehab497
Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Górriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 Aug 23; doi: 10.1093/eurheartj/ehab497. Epub 2021 Aug 23. PMID: 34423370.
Copy Download .nbib Format: NLM
Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?.

Journal of personalized medicine

DiGuardo MA, Kester SJ, Mahaffey VJ, Hammel SA, Heaser KK, Hofich CD, Tauscher CD, Kerr SE, Oliveira JL, Jacob EK, Moyer AM.
PMID: 33316904
J Pers Med. 2020 Dec 09;10(4). doi: 10.3390/jpm10040268.

PURPOSE: molecular testing is often indicated for recently transfused patients. However, there are no guidelines regarding the potential interference from donor DNA or whether it is necessary to wait for a period of time post-transfusion prior to genetic testing....

Cite
DiGuardo MA, Kester SJ, Mahaffey VJ, et al. Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?. J Pers Med. 2020;10(4)doi: 10.3390/jpm10040268.
DiGuardo, M. A., Kester, S. J., Mahaffey, V. J., Hammel, S. A., Heaser, K. K., Hofich, C. D., Tauscher, C. D., Kerr, S. E., Oliveira, J. L., Jacob, E. K., & Moyer, A. M. (2020). Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?. Journal of personalized medicine, 10(4), . https://doi.org/10.3390/jpm10040268
DiGuardo, Maggie A, et al. "Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?." Journal of personalized medicine vol. 10,4 (2020). doi: https://doi.org/10.3390/jpm10040268
DiGuardo MA, Kester SJ, Mahaffey VJ, Hammel SA, Heaser KK, Hofich CD, Tauscher CD, Kerr SE, Oliveira JL, Jacob EK, Moyer AM. Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?. J Pers Med. 2020 Dec 09;10(4). doi: 10.3390/jpm10040268. PMID: 33316904; PMCID: PMC7768420.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 122 entries